comprehensive -WSS

comprehensive

author：leisure time 2025-09-29 21:26:43 - browse：35

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Psychedelics group wrestles with new pharma identity

leisure time

WSS

ReNAgade cuts staff seven months after raising $300 million

Heart attack and stroke risk calculators need revising

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Hollywood unions extend contract negotiations for actors

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Cigna, Humana reportedly in talks to merge

leisure time

comprehensive

hotspot

The high cost of giving birth even with insurance

Trump demands the U.S. pay no more for drugs than other countries … again

Guidelines to prevent youth baseball injuries need more muscle

Hepatitis C has a cure — but many Americans still lack access to it

After affirmative action ruling, medical educators look to 'holistic review'

Jerome Adams on the need for new antivirals for Covid

Medical leaders decry Supreme Court decision on affirmative action

Organ aging and disease risk measured by new blood test

New air purifier tech could be key to improving indoor air quality

New air purifier tech could be key to improving indoor air quality

explore

Flagship Pioneering launches a new biotech in two countries

In Memoriam: Notable people who died in 2023

Mayo Clinic plans $5B tech

UnitedHealth’s Optum accused of antitrust violations in California

The high cost of giving birth even with insurance

Tori Bowie and the unacceptable rates of Black maternal death

focus

leisure time

knowledge

Wikipedia